News and Events
Learn more about current happenings at Ergomed.
London, UK – 02 July 2018: Ergomed plc, (LSE:ERGO) (“Ergomed” or the “Company”) a company focused on providing specialised services to the pharmaceutical industry, today announces a change to its Board and management team with the appointment of Stuart Jackson as Chief Financial Officer with immediate effect.
Stuart brings with him 20 years’ experience at Chief Financial Officer level, having managed companies on the London, NASDAQ and Oslo Stock Exchanges. He has significant international experience in early stage and growth companies as well as managing significant and complex change projects. Stuart’s experience has been gained primarily in the energy and technology/telecommunications sectors where consistent project service delivery across a number of geographies has been a key feature of business success.
He was Chief Financial Officer at Acergy SA responsible for the financial restructuring of the business and implementation of the new business strategy which took Acergy from $0.1bn to $6.0bn market capitalisation over a four year period. More recently he was Chief Financial Officer at CEONA, a Goldman Sachs Capital Partners group of companies, where he was responsible for the early stage set-up and growth of the business and Bibby Offshore Holdings Limited where, as Chief Financial Officer, he also managed the strategic development and M&A activities and oversaw its recent recapitalisation.
Stephen Stamp, Chief Executive Officer of Ergomed commented: “Stuart brings to Ergomed a strong track record of delivery within project and service related businesses on an international scale. His experience in non-healthcare services businesses will provide a broader perspective to our project delivery and he will play an integral role in enhancing the strong foundations of Ergomed as we seek to deliver our strategy of taking a market leading positon. I very much look forward to working closely with Stuart in the next stage of our exciting development.”
Peter George, Chairman of Ergomed commented: “I am very pleased to welcome Stuart to the Ergomed plc board. His expertise and experience across a broad range of businesses will be invaluable as we continue to grow our services and expand into new related areas.”
Stuart holds a BSc in Accounting & Financial Management from Loughborough University of Technology and he is a Fellow of the Chartered Institute of Management Accountants. He has a beneficial holding of 1,845 ordinary shares in the Company.
Save as disclosed below, in relation to current and prior directorships, Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Stuart Jackson’s appointment. Mr Stuart Robert Jackson, aged 58, currently holds and has held the following directorships in the past five years:
Amava Resorts Pty
Key Energy Finance Limited
Tortuga Energy Services Limited
Directorships in the past five years:
Bibby Offshore Holdings Limited
Bibby Offshore Services Plc
Bibby Subsea Inc.
Bibby Subsea Rov
Ceona Chartering (UK) Limited
Ceona Contracting (UK) Limited
Ceona Equipment Limited
Ceona Holding Ltd
Ceona Investments Limited
Ceona Pte. Ltd.
Ceona Services (UK) Limited
Ceona Ship 1 Limited
Ceona Ship 2 Limited
Ceona Ship 3 Limited
Ceona Ship Holdings Limited
Newco 987 Limited
Oig Giant I Pte. Ltd.
Oig Giant Ii Pte. Ltd.
Project Development International Limited
Ergomed plc Tel: +44 (0) 1483 503 205
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0) 20 7496 3000
Aubrey Powell (Joint Broker)
Consilium Strategic Communications – for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Olivia Manser email@example.com
MC Services – for Continental European enquiries Tel: +49 211 5292 5222
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: https://ergomedplc.com.